CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

rubitecan

Small moleculeexperimental

Rubitecan is an oral topoisomerase inhibitor, developed by SuperGen. — Wikipedia

Clinical trial activity

20 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
17
Phase 3
4
Phase 4
0

Earliest trial started Nov 1, 1998 (NCT00005869)

Timeline

1990s

  1. Jan 1, 1998

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 1999

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Jan 1, 2000

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c([N+](=O)[O-])cccc3nc2-1
Mol. weight
393.36 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 9-nc
  • 9-nc
  • 9-nitro-20(s)-camptothecin
  • 9-nitrocamptothecin
  • 9-nitrocamptothecin
  • 9-nitrocamptothecin
  • 9-nitrocamptothecin
  • 9-nitrocamptothecin, (s)-isomer
  • nitrocamptothecin
  • nitrocamptothecin
  • orathecin
  • rfs2000
  • rfs 2000
  • rfs-2000
  • rfs-2000
  • rfs-2000
  • rubitecan
  • rubitecan
  • rubitecan
  • rubitecan
  • rubitecan
  • rubitecan
  • rubitecan

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00113256Phase 2/Phase 3 (Phase 3)Feb 1, 2005Astex Pharmaceuticals, Inc.
NCT00250068Phase 2Apr 1, 2003University of New Mexico
NCT00249990Phase 2Apr 1, 2003Baylor University, University of New Mexico
NCT00113113Phase 1Aug 1, 2001Astex Pharmaceuticals, Inc.
NCT00006267Phase 2Sep 11, 2000Gynecologic Oncology Group, National Cancer Institute (NCI), Northwestern University
NCT00006047Phase 1Jun 1, 2000Astex Pharmaceuticals, Inc., National Cancer Institute (NCI), University of South Florida
NCT00005820Phase 2May 1, 2000Georgetown University, National Cancer Institute (NCI)
NCT00006026Phase 2May 1, 2000Centre Georges Francois Leclerc, European Organisation for Research and Treatment of Cancer
NCT00006082Phase 2May 1, 2000Centre Georges Francois Leclerc, European Organisation for Research and Treatment of Cancer
NCT00006230Phase 2May 1, 2000Centre Georges Francois Leclerc, European Organisation for Research and Treatment of Cancer
NCT00005876Phase 2Apr 1, 2000Astex Pharmaceuticals, Inc.
NCT00005826Phase 2Mar 1, 2000European Organisation for Research and Treatment of Cancer, Institut Gustave Roussy
NCT00005877Phase 2Sep 1, 1999Astex Pharmaceuticals, Inc.
NCT00005873Phase 2Sep 1, 1999Astex Pharmaceuticals, Inc.
NCT00005874Phase 2Jun 1, 1999Astex Pharmaceuticals, Inc.
NCT00005872Phase 2May 1, 1999Astex Pharmaceuticals, Inc.
NCT00005870Phase 3Mar 1, 1999Astex Pharmaceuticals, Inc.
NCT00005875Phase 2Jan 1, 1999Astex Pharmaceuticals, Inc.
NCT00005869Phase 3Nov 1, 1998Astex Pharmaceuticals, Inc.
NCT00005871Phase 3Nov 1, 1998Astex Pharmaceuticals, Inc.
Showing 20 of 20 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Astex Pharmaceuticals, Inc.For profit121131998
European Organisation for Research and Treatment of CancerAcademic/Hospital4412000
Centre Georges Francois LeclercAcademic/Hospital3012000
National Cancer Institute (NCI)Government3122000
University of New MexicoAcademic/Hospital2212003
Baylor UniversityAcademic/Hospital1012003
Georgetown UniversityAcademic/Hospital1012000
Gynecologic Oncology GroupAcademic/Hospital1112000
Institut Gustave RoussyAcademic/Hospital1012000
Northwestern UniversityAcademic/Hospital1012000
University of South FloridaAcademic/Hospital1112000
11 organizations
Page 1 / 1